[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-of-unknown-primary-site\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-of-unknown-primary-site":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100401235","tcf-001-track-target-rare-cancer-knowledge-study-100401235",false,"NCT04504604","TCF-001 TRACK (Target Rare Cancer Knowledge) Study","TRACK","INCLUSION CRITERIA\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study related blood draws and assessments for the duration of the study.\n* Individuals who are 18 years old or older at the time of consent.\n* Patients with a rare (fewer than 6 cases per 100,000 per year) solid tumor or lymphoma with evaluable disease at baseline. The complete list of included cancers are included in the study protocol; diseases not listed in the study protocol may be enrolled with the approval of the Principal Investigator.\n* May or may not have had qualifying (by Foundation Medicine) comprehensive genomic profiling before the present study. For those who have had qualifying comprehensive genomic profiling performed prior to the present study, the archival specimen tested must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.\n* Willingness to provide existing archived and\u002For newly collected tissue resulting from standard of care procedures and blood samples for genomic profiling. If the submitted sample is determined to be insufficient for testing, the patient will be considered to be a screen failure.\n* For archival tissue to be used for comprehensive genomic profiling for the present study, that specimen must have been harvested within 18 months of the baseline visit (i.e. date of consent) of the present study.\n* Willingness to provide clinical and medical information to the study team as required.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Ability to read, write and communicate in English.\n* Ability to review and sign a web-based informed consent form, or review and sign an informed consent form in treating physician office.\n* Resides within the United States.\n\nEXCLUSION CRITERIA\n\n* Participants who are unable to provide informed consent.\n* Participants who are 17 years of age or younger.\n* Participants who are unable to comply with the study procedures.\n* Known existence of an uncontrolled intercurrent illness including, but not limited to, psychiatric illness or social situations that would impair compliance with study requirements.\n* Concurrent active malignancy requiring treatment within 1 year of enrollment, at the discretion of treating physician.\n* Pregnancy or breastfeeding.\n* Any unlisted criteria at the discretion of the treating physician.","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"NA","This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.",[26,27,28],"Rare Cancers","Cholangiocarcinoma","Cancer of Unknown Primary Site",[30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"genomics","precision medicine","molecular tumor board","remote participation","targeted therapy","patient reported outcomes","understudied diseases","comprehensive genomic profiling","virtual","next generation sequencing","liquid biopsies","tumor biopsies","cell-free DNA","biomarker testing","solid tumors","RECRUITING","2026-05-21",{"date":48,"type":49},"2026-05-26","ACTUAL",{"date":51,"type":49},"2020-10-01",{"date":53,"type":20},"2028-12",{"name":55,"class":56},"TargetCancer Foundation","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":16,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":69,"studyType":70,"phases":4,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":57},"100621618","18f-fapi-pet-in-cancers-of-unknown-primary-site-100621618","NCT07372963","18F-FAPI PET in Cancers of Unknown Primary Site","Prospective Clinical Study and Exploration of 18F-FAPI PET\u002FCT Imaging in Cancers of Unknown Primary Site","Inclusion Criteria:\n\n1. Patients with clinical or imaging suspicion of cancer of unknown primary origin.\n2. Patients with 18F FAPI PET scans.\n\nExclusion Criteria:\n\n1. Concurrent presence of other active malignant tumors or a history of other malignant tumors within the past 5 years;\n2. Severe uncontrollable diseases or active infections;\n3. Ineligible participants for project informed consent.\n4. Pregnant and lactating women.","20 Years","85 Years",{"count":68,"type":20},120,"3 Years","OBSERVATIONAL","This study aims to evaluate the diagnostic efficacy, therapeutic assessment, prognostic analysis, and impact on clinical treatment decisions of 18F-FAPI PET\u002FCT in patients with cancer of unknown primary.",[28],"NOT_YET_RECRUITING","2026-01-20",{"date":76,"type":49},"2026-01-28",{"date":78,"type":20},"2026-02-01",{"date":80,"type":20},"2028-12-31",{"name":82,"class":56},"First Affiliated Hospital of Zhejiang University",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100621083","the-norcup-trial-improving-prognosis-and-personalized-treatment-in-cancer-of-unknown-primary-cup-100621083","NCT07366008","The NorCUP Trial: Improving Prognosis and Personalized Treatment in Cancer of Unknown Primary (CUP)","NorCUP","Inclusion Criteria:\n\n* ECOG PS 0-2.\n* Life expectancy minimum 3 months.\n* Radiologically verified metastatic disease (CT thorax\u002Fabdomen\u002Fpelvis) with no radiological signs of primary tumor.\n* Histologically verified metastatic disease of unknown primary. Morphological and immunohistochemical findings suggesting a possible, but not definitive, origo is eligible.\n* Eligible histologies include adenocarcinoma, squamous cell carcinoma, poorly and undifferentiated carcinoma and undifferentiated neoplasms.\n* Clinically relevant endoscopic examinations have been performed as indicated by clinical, radiological and pathological findings, without identification of a primary tumor.\n* Clinically relevant supplementary radiological examinations have been performed as indicated by clinical, radiological and pathological findings, with no radiological signs of primary tumor (e.g. PET\u002FCT, mammography\u002FMR mammae).\n* Metastatic lesion available for biopsy. Protocol deviation may be allowed if lesion is not technically available for biopsy. For patients with metastatic lesion technically available for biopsy, the patient must be deemed medically fit to undergo a metastatic biopsy, as assessed by the investigator.\n* Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\nExclusion Criteria:\n\n* Patients with any clinically significant medical or psychiatric condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements.\n* Psychological, familial, sociological or geographical condition(s) potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial\n* Patient not able to give an informed consent or comply with study regulations as deemed by study investigator.",{"count":91,"type":20},350,[23],"The goal of this clinical trial is to improve diagnosis and treatment strategies for patients with Cancer of Unknown Primary (CUP) by using advanced molecular profiling to identify the likely tumor origin and guide therapy.\n\nThe main questions it aims to answer are:\n\nCan comprehensive molecular profiling help determine the origin of CUP tumors? Does identifying the tumor origin improve treatment choices and survival outcomes compared to historical data?\n\nParticipants will:\n\n* Undergo a new biopsy to collect tumor tissue for advanced analyses.\n* Provide blood samples for circulating tumor DNA (cfDNA\u002FctDNA) analyses.\n* Provide a fecal sample for microbiome analysis.\n* Have their tumor tissue analyzed using:\n\nMethylation profiling and comprehensive gene panel testing.\n\n* Have the results reviewed in a specialized CUP molecular MDT meeting to determine the likely tumor origin and guide treatment.\n* Have their tumor tissue samples biobanked for further exploratory whole genome sequencing (WGS) and RNA sequencing.",[28],[96,97],"cancer of unknown primary site","neoplasms, unknown primary","2026-01-16",{"date":100,"type":49},"2026-01-26",{"date":102,"type":20},"2026-01",{"date":104,"type":20},"2033-01",{"name":106,"class":56},"Haukeland University Hospital",6]